Role of Glucagon-like peptide-1 analogue versus Amylin as an adjuvant therapy in type 1 diabetes in a closed loop setting with ePID algorithm

Venkat Sasidhar Renukuntla, Neesha Ramchandani, Jeniece Trast, Martin Cantwell, Rubina A. Heptulla

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Aims/Hypothesis: Postprandial hyperglycemia due to paradoxical hyperglucagonemia is a major challenge of diabetes treatment despite the use of the artificial pancreas. We postulated that adjunctive therapy with pramlintide or exenatide would attenuate hyperglycemia in the postprandial phase through glucagon suppression, thereby optimizing the functioning of the closed-loop (CL) system. Methods: Subjects with type 1 diabetes (T1DM) on insulin pump therapy were recruited to participate in a 27-hour hospitalized admission on 3 occasions (2-4 weeks apart) and placed on the insulin delivery via CL system in random order to receive (1) insulin alone (control), (2) exenatide 2.5 μg + insulin, (3) pramlintide 30 μg + insulin. Medications were given prior to lunch and dinner, which was a standardized meal of 60 grams of carbohydrates. Insulin delivery was as per the ePID algorithm via the Medtronic CL system and continuous subcutaneous glucose monitoring via Medtronic Sof-sensors. Ten subjects age 23 ± 1 years with a HbA1c of 7.29 ± 0.3% (56 ± 1 mmol/mol) and duration of T1DM 10.6 ± 2.0 years participated in the 3-part study. Results: Exenatide was found to be significantly better in attenuating postprandial hyperglycemia as compared to insulin monotherapy (P <.03) and pramlintide (P > .05). Glucagon suppression was statistically significant with exenatide (P <.03) as compared to pramlintide. Insulin requirements were lower with adjunctive therapy, but statistically insignificant. Conclusions/Interpretations: Insulin monotherapy results in postprandial hyperglycemia in T1DM in the CL setting and adjunctive therapy with exenatide reduces postprandial hyperglycemia effectively and should be considered as adjunctive therapy in T1DM.

Original languageEnglish (US)
Pages (from-to)1011-1017
Number of pages7
JournalJournal of diabetes science and technology
Volume8
Issue number5
DOIs
StatePublished - Jan 1 2014

Fingerprint

Islet Amyloid Polypeptide
Glucagon-Like Peptide 1
Insulin
Medical problems
Type 1 Diabetes Mellitus
Peptides
Hyperglycemia
Closed loop systems
Therapeutics
Glucagon
Meals
Artificial Pancreas
Lunch
Carbohydrates
Glucose
exenatide
Pumps

Keywords

  • artificial pancreas
  • closed loop
  • ePID algorithm
  • exenatide
  • pramlintide
  • type 1 diabetes

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine
  • Bioengineering
  • Biomedical Engineering

Cite this

Role of Glucagon-like peptide-1 analogue versus Amylin as an adjuvant therapy in type 1 diabetes in a closed loop setting with ePID algorithm. / Renukuntla, Venkat Sasidhar; Ramchandani, Neesha; Trast, Jeniece; Cantwell, Martin; Heptulla, Rubina A.

In: Journal of diabetes science and technology, Vol. 8, No. 5, 01.01.2014, p. 1011-1017.

Research output: Contribution to journalArticle

Renukuntla, Venkat Sasidhar ; Ramchandani, Neesha ; Trast, Jeniece ; Cantwell, Martin ; Heptulla, Rubina A. / Role of Glucagon-like peptide-1 analogue versus Amylin as an adjuvant therapy in type 1 diabetes in a closed loop setting with ePID algorithm. In: Journal of diabetes science and technology. 2014 ; Vol. 8, No. 5. pp. 1011-1017.
@article{3756c00e4bbb40b48b3fcc492d8a7931,
title = "Role of Glucagon-like peptide-1 analogue versus Amylin as an adjuvant therapy in type 1 diabetes in a closed loop setting with ePID algorithm",
abstract = "Aims/Hypothesis: Postprandial hyperglycemia due to paradoxical hyperglucagonemia is a major challenge of diabetes treatment despite the use of the artificial pancreas. We postulated that adjunctive therapy with pramlintide or exenatide would attenuate hyperglycemia in the postprandial phase through glucagon suppression, thereby optimizing the functioning of the closed-loop (CL) system. Methods: Subjects with type 1 diabetes (T1DM) on insulin pump therapy were recruited to participate in a 27-hour hospitalized admission on 3 occasions (2-4 weeks apart) and placed on the insulin delivery via CL system in random order to receive (1) insulin alone (control), (2) exenatide 2.5 μg + insulin, (3) pramlintide 30 μg + insulin. Medications were given prior to lunch and dinner, which was a standardized meal of 60 grams of carbohydrates. Insulin delivery was as per the ePID algorithm via the Medtronic CL system and continuous subcutaneous glucose monitoring via Medtronic Sof-sensors. Ten subjects age 23 ± 1 years with a HbA1c of 7.29 ± 0.3{\%} (56 ± 1 mmol/mol) and duration of T1DM 10.6 ± 2.0 years participated in the 3-part study. Results: Exenatide was found to be significantly better in attenuating postprandial hyperglycemia as compared to insulin monotherapy (P <.03) and pramlintide (P > .05). Glucagon suppression was statistically significant with exenatide (P <.03) as compared to pramlintide. Insulin requirements were lower with adjunctive therapy, but statistically insignificant. Conclusions/Interpretations: Insulin monotherapy results in postprandial hyperglycemia in T1DM in the CL setting and adjunctive therapy with exenatide reduces postprandial hyperglycemia effectively and should be considered as adjunctive therapy in T1DM.",
keywords = "artificial pancreas, closed loop, ePID algorithm, exenatide, pramlintide, type 1 diabetes",
author = "Renukuntla, {Venkat Sasidhar} and Neesha Ramchandani and Jeniece Trast and Martin Cantwell and Heptulla, {Rubina A.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1177/1932296814542153",
language = "English (US)",
volume = "8",
pages = "1011--1017",
journal = "Journal of diabetes science and technology",
issn = "1932-2968",
publisher = "Diabetes Technology Society",
number = "5",

}

TY - JOUR

T1 - Role of Glucagon-like peptide-1 analogue versus Amylin as an adjuvant therapy in type 1 diabetes in a closed loop setting with ePID algorithm

AU - Renukuntla, Venkat Sasidhar

AU - Ramchandani, Neesha

AU - Trast, Jeniece

AU - Cantwell, Martin

AU - Heptulla, Rubina A.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Aims/Hypothesis: Postprandial hyperglycemia due to paradoxical hyperglucagonemia is a major challenge of diabetes treatment despite the use of the artificial pancreas. We postulated that adjunctive therapy with pramlintide or exenatide would attenuate hyperglycemia in the postprandial phase through glucagon suppression, thereby optimizing the functioning of the closed-loop (CL) system. Methods: Subjects with type 1 diabetes (T1DM) on insulin pump therapy were recruited to participate in a 27-hour hospitalized admission on 3 occasions (2-4 weeks apart) and placed on the insulin delivery via CL system in random order to receive (1) insulin alone (control), (2) exenatide 2.5 μg + insulin, (3) pramlintide 30 μg + insulin. Medications were given prior to lunch and dinner, which was a standardized meal of 60 grams of carbohydrates. Insulin delivery was as per the ePID algorithm via the Medtronic CL system and continuous subcutaneous glucose monitoring via Medtronic Sof-sensors. Ten subjects age 23 ± 1 years with a HbA1c of 7.29 ± 0.3% (56 ± 1 mmol/mol) and duration of T1DM 10.6 ± 2.0 years participated in the 3-part study. Results: Exenatide was found to be significantly better in attenuating postprandial hyperglycemia as compared to insulin monotherapy (P <.03) and pramlintide (P > .05). Glucagon suppression was statistically significant with exenatide (P <.03) as compared to pramlintide. Insulin requirements were lower with adjunctive therapy, but statistically insignificant. Conclusions/Interpretations: Insulin monotherapy results in postprandial hyperglycemia in T1DM in the CL setting and adjunctive therapy with exenatide reduces postprandial hyperglycemia effectively and should be considered as adjunctive therapy in T1DM.

AB - Aims/Hypothesis: Postprandial hyperglycemia due to paradoxical hyperglucagonemia is a major challenge of diabetes treatment despite the use of the artificial pancreas. We postulated that adjunctive therapy with pramlintide or exenatide would attenuate hyperglycemia in the postprandial phase through glucagon suppression, thereby optimizing the functioning of the closed-loop (CL) system. Methods: Subjects with type 1 diabetes (T1DM) on insulin pump therapy were recruited to participate in a 27-hour hospitalized admission on 3 occasions (2-4 weeks apart) and placed on the insulin delivery via CL system in random order to receive (1) insulin alone (control), (2) exenatide 2.5 μg + insulin, (3) pramlintide 30 μg + insulin. Medications were given prior to lunch and dinner, which was a standardized meal of 60 grams of carbohydrates. Insulin delivery was as per the ePID algorithm via the Medtronic CL system and continuous subcutaneous glucose monitoring via Medtronic Sof-sensors. Ten subjects age 23 ± 1 years with a HbA1c of 7.29 ± 0.3% (56 ± 1 mmol/mol) and duration of T1DM 10.6 ± 2.0 years participated in the 3-part study. Results: Exenatide was found to be significantly better in attenuating postprandial hyperglycemia as compared to insulin monotherapy (P <.03) and pramlintide (P > .05). Glucagon suppression was statistically significant with exenatide (P <.03) as compared to pramlintide. Insulin requirements were lower with adjunctive therapy, but statistically insignificant. Conclusions/Interpretations: Insulin monotherapy results in postprandial hyperglycemia in T1DM in the CL setting and adjunctive therapy with exenatide reduces postprandial hyperglycemia effectively and should be considered as adjunctive therapy in T1DM.

KW - artificial pancreas

KW - closed loop

KW - ePID algorithm

KW - exenatide

KW - pramlintide

KW - type 1 diabetes

UR - http://www.scopus.com/inward/record.url?scp=84929780489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929780489&partnerID=8YFLogxK

U2 - 10.1177/1932296814542153

DO - 10.1177/1932296814542153

M3 - Article

C2 - 25030181

AN - SCOPUS:84929780489

VL - 8

SP - 1011

EP - 1017

JO - Journal of diabetes science and technology

JF - Journal of diabetes science and technology

SN - 1932-2968

IS - 5

ER -